

CLAIMS

Claim 1. (Previously amended): A method for treating a patient that has osteoporosis and is being administered cyclase activating parathyroid hormone (CAP) or analogues thereof comprising also administering a cyclase inhibiting parathyroid hormone peptide (CIP) having amino acid sequence from between PTH₂₋₈₄ (SEQ ID NO:1) and PTH₃₄₋₈₄ (SEQ ID NO:3) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.

Claim 2. (Previously amended): The method of claim 1 wherein the peptide has an amino acid sequence from between PTH₃₋₈₄ (SEQ ID NO:2) and PTH₂₈₋₈₄ (SEQ ID NO:8).

Claim 3. (Original): The method of Claim 1 wherein one determines the amount of CAP and CIP present in the patient.

Claim 4. (Original): The method of Claim 3 wherein the CIP administration is performed in a pulsatile manner.

Claim 5. (Previously amended): A method for treating a patient that has osteoporosis comprising administering a cyclase inhibiting parathyroid hormone peptide (CIP) having amino acid sequence from between PTH₂₋₈₄ (SEQ ID NO:1) and PTH₃₄₋₈₄ (SEQ ID NO:3) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.

Claim 6. (Previously amended): The method of claim 5 wherein the peptide has an amino acid sequence from between PTH₃₋₈₄ (SEQ ID NO:2) and PTH₂₈₋₈₄ (SEQ ID NO:8).

Claim 7. (Original): The method of Claim 5 wherein one determines the amount of CAP and CIP present in the patient.

Clam 8. (Original): The method of Claim 7 wherein the CIP administration is performed in a pulsatile manner.